Combination of Roche medicines Cotellic and Zelboraf approved in Switzerland for the treatment of patients with advanced melanoma
Posted: 27 August 2015 |
New treatment option for patients with difficult-to-treat form of skin cancer has shown improved treatment outcomes…
Roche has announced that the Swiss licensing and supervisory authority for therapeutic products (Swissmedic) has approved combination therapy with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of patients with advanced melanoma. This makes Switzerland the first country where this combination therapy is available to patients.
The approval of Zelboraf in 2011 represented a first improvement in therapy for patients with advanced melanoma. Zelboraf, which selectively inhibits the MAPK signalling mechanism in the cancer cell (the mutated protein kinase BRAF), was able to prolong overall survival by 4 months (median overall survival 13.6 months) compared to the standard chemotherapy, dacarbazine.
Researchers discovered frequent activation of a further protein kinase, MEK, in BRAF-mutant melanoma. This discovery led to the development of Cotellic, a MEK inhibitor. Dual inhibition of BRAF and MEK in the MAPK signalling pathway was the second breakthrough in targeted melanoma therapy. The pivotal coBRIM study showed that the combination of Cotellic and Zelboraf significantly prolongs the time to disease progression. Median survival until disease progression was 12.3 months. The coBRIM data were published in the New England Journal of Medicine in November 2014.
Professori Reinhard Dummer MD, Deputy Head, Department of Dermatology, Zurich University Hospital: “This combination therapy is the result of systematic further development of BRAF and MEK inhibitor monotherapy. Combination therapy results in higher response rates and significantly prolonged progression-free intervals.”
Melanoma is less common, but more aggressive than other forms of skin cancer. BRAF is mutated in approximately half of melanomas. When melanoma is diagnosed early, it is generally a curable disease, but most people with advanced melanoma have a poor prognosis. More than 232,000 people worldwide are currently diagnosed with melanoma each year and more than 55,000 people worldwide die every year from melanoma skin cancers. In recent years, there have been significant advances in treatment for metastatic melanoma and people with the disease have more options. However, it continues to be a serious health issue with a high unmet need and a steadily increasing incidence over the past 30 years.
Zelboraf was the first prescription treatment for patients with unresectable or metastatic melanoma with BRAF V600 mutation as detected by a validated test, such as Roche’s cobas 4800 BRAF Mutation Test. Zelboraf is not indicated for use in patients with wild-type BRAF melanoma. It is now approved in more than 90 countries and has been used to treat more than 11,000 patients worldwide. Zelboraf was co-developed under a 2006 licence and collaboration agreement between Roche and Plexxikon, now a member of the Daiichi Sankyo Group.
Cotellic (GDC-0973, XL518) was discovered by Exelixis Inc. and is being developed in collaboration with Exelixis. Cotellic is also being investigated in combination with several investigational medicines, including an immunotherapy, in several tumour types such as non-small cell lung cancer and colorectal cancer.
About the Cotellic and Zelboraf combination
Cotellic is designed to selectively block the activity of MEK, one of a series of proteins inside cells that make up a signalling pathway that helps regulate cell division and survival. Cotellic binds to MEK while Zelboraf binds to mutant BRAF, another protein on the pathway, to interrupt abnormal signalling that can cause tumours to grow.
About the coBRIM study
The pivotal coBRIM study is an international, randomised, double-blind, placebo-controlled, Phase III study evaluating the safety and efficacy of the combination therapy. A total of 495 patients with unresectable, locally advanced or metastatic melanoma with a BRAF V600 mutation were randomised to receive Zelboraf once daily at the approved dosage and either Cotellic or a placebo for 3 weeks followed by one week off Cotellic/placebo. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent. Investigator-assessed progression-free survival (PFS) is the primary endpoint. Secondary endpoints include PFS by independent review committee, objective response rate, overall survival, duration of response and other safety, pharmacokinetic and quality of life measures.
The coBRIM results showed that patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of more than a year (12.3 months) without progression of their disease (progression-free survival, PFS) on combination therapy with Cotellic and Zelboraf, and only 7.2 months on Zelboraf monotherapy.
Patients treated with Cotellic and Zelboraf also responded better to treatment than those given Zelboraf alone. The objective response rate (ORR) of the Cotellic and Zelboraf combination was 70 percent (compared to 50 percent for monotherapy). With further follow-up, the complete response rate increased from 10 percent to 15 percent with the combination as some patients who had a partial response achieved a complete response after more than one year of treatment. The safety profile of Cotellic and Zelboraf was consistent with safety data previously reported from the Phase Ib BRIM7 study. The most common adverse events in the combination arm were diarrhea, rash, nausea, fever, sun sensitivity, liver lab abnormalities, elevated creatine phosphokinase (CPK, an enzyme released by muscles) and vomiting.